Green Cross Corp (006280) - Total Assets

Latest as of September 2025: ₩3.19 Trillion KRW ≈ $2.16 Billion USD

Based on the latest financial reports, Green Cross Corp (006280) holds total assets worth ₩3.19 Trillion KRW (≈ $2.16 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Green Cross Corp to assess the company's total reinvestment commitment from operating cash flow.

Green Cross Corp - Total Assets Trend (2003–2024)

This chart illustrates how Green Cross Corp's total assets have evolved over time, based on quarterly financial data. Explore 006280 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Green Cross Corp - Asset Composition Analysis

Current Asset Composition (December 2024)

Green Cross Corp's total assets of ₩3.19 Trillion consist of 43.8% current assets and 56.2% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 0.8%
Accounts Receivable ₩386.53 Billion 14.1%
Inventory ₩746.58 Billion 27.2%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩181.77 Billion 6.6%
Goodwill ₩125.61 Billion 4.6%

Asset Composition Trend (2003–2024)

This chart illustrates how Green Cross Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 006280 stock market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Green Cross Corp's current assets represent 43.8% of total assets in 2024, an increase from 0.0% in 2003.
  • Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 3.2% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 4.0% in 2003.
  • Asset Diversification: The largest asset category is inventory at 27.2% of total assets.

Green Cross Corp Competitors by Total Assets

Key competitors of Green Cross Corp based on total assets are shown below.

Company Country Total Assets
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
SIMCERE PHARMAC. GRP LTD
F:S2P
Germany €14.73 Billion
Curaleaf Holdings Inc.
TO:CURA
Canada CA$2.88 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Walvax BioTech
SHE:300142
China CN¥11.13 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion

Green Cross Corp - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.18 1.55 1.92
Quick Ratio 0.51 0.70 1.18
Cash Ratio 0.00 0.00 0.00
Working Capital ₩223.84 Billion ₩432.09 Billion ₩542.64 Billion

Green Cross Corp - Advanced Valuation Insights

This section examines the relationship between Green Cross Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.15
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 3.8%
Total Assets ₩2.74 Trillion
Market Capitalization $1.01 Billion USD

Valuation Analysis

Below Book Valuation: The market values Green Cross Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Green Cross Corp's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Green Cross Corp (2003–2024)

The table below shows the annual total assets of Green Cross Corp from 2003 to 2024.

Year Total Assets Change
2024-12-31 ₩2.74 Trillion
≈ $1.86 Billion
+3.80%
2023-12-31 ₩2.64 Trillion
≈ $1.79 Billion
+4.66%
2022-12-31 ₩2.53 Trillion
≈ $1.71 Billion
+2.57%
2021-12-31 ₩2.46 Trillion
≈ $1.67 Billion
+14.44%
2020-12-31 ₩2.15 Trillion
≈ $1.46 Billion
+9.80%
2019-12-31 ₩1.96 Trillion
≈ $1.33 Billion
+13.69%
2018-12-31 ₩1.72 Trillion
≈ $1.17 Billion
+1.16%
2017-12-31 ₩1.70 Trillion
≈ $1.15 Billion
+9.86%
2016-12-31 ₩1.55 Trillion
≈ $1.05 Billion
+9.57%
2015-12-31 ₩1.42 Trillion
≈ $959.01 Million
+6.37%
2014-12-31 ₩1.33 Trillion
≈ $901.56 Million
+20.47%
2013-12-31 ₩1.10 Trillion
≈ $748.34 Million
+15.70%
2012-12-31 ₩954.38 Billion
≈ $646.77 Million
+10.93%
2011-12-31 ₩860.35 Billion
≈ $583.05 Million
+16.06%
2010-12-31 ₩741.30 Billion
≈ $502.37 Million
+104.40%
2006-12-31 ₩362.68 Billion
≈ $245.78 Million
+22.22%
2005-12-31 ₩296.73 Billion
≈ $201.09 Million
+18.32%
2004-12-31 ₩250.79 Billion
≈ $169.96 Million
+184.80%
2003-12-31 ₩88.06 Billion
≈ $59.68 Million
--

About Green Cross Corp

KO:006280 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$1.01 Billion
₩1.49 Trillion KRW
Market Cap Rank
#9024 Global
#245 in Korea
Share Price
₩130600.00
Change (1 day)
-0.38%
52-Week Range
₩118700.00 - ₩180300.00
All Time High
₩493171.17
About

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more